Medigrowth backs National Pain Week as Gold Sponsor

Medigrowth will serve as Gold Sponsor of National Pain Week 2026, a Chronic Pain Australia campaign running July 26-31 to support Australians living with chronic pain. The partnership centers on patient education, stigma reduction and growing interest in medicinal cannabis as a pain-management option.

Why it matters: - Chronic pain affects 5.4 million Australians, making awareness, access to information and care a major public health issue. - Chronic Pain Australia says the partnership with Medigrowth is intended to elevate lived experience, reduce stigma and help consumers make informed healthcare decisions with qualified health professionals. - National Pain Week is tied to the National Pain Survey, which tracks the experiences of Australians living with chronic pain.

What happened: - Medigrowth was announced as Gold Sponsor of National Pain Week 2026. - National Pain Week runs from 26 to 31 July 2026. - Chronic Pain Australia said Medigrowth will also be Gold Sponsor of the 2026 National Pain Report. - Medigrowth produced a five-part video series for the campaign and a longer-form interview on pain and women’s health.

The details: - The video series answers questions about medicinal cannabis, including what it is, what it feels like, whether other people will know someone has tried it, whether it will work and whether it will get a person high. - The women’s health interview is titled “Pain Lives in Women’s Health.” - The interview features Medigrowth’s Melanie Wentzel and Chronic Pain Australia General Manager Kellie Jade Ellis. - The discussion covers healthcare leadership and Ellis’s endometriosis journey. - Chronic Pain Australia’s past three National Pain Reports show a growing role for medicinal cannabis in chronic pain management. - In 2025, 31% of respondents had accessed medicinal cannabis for pain management, up from 28% in 2024. - Another 27.5% said they would like to or intend to try medicinal cannabis. - More than half of respondents either use medicinal cannabis or are interested in it as a treatment option. - Cost and driving restrictions have each eased slightly year over year as reported barriers. - Medigrowth’s broader work includes clinical research, cannabinoid therapeutics for the Australian market and patient support through its digital health platform, Azure Health. - Medigrowth says its focus areas include women’s health, paediatric populations and chronic pain. - Medigrowth cites a randomised, double-blind, placebo-controlled CBD trial with Deakin University and Swinburne University in children and families living with autism. - Medigrowth also cites the EMPOWER Project, a prospective HREC-approved real-world evidence study following up to 5,000 patients over four years. - Chronic Pain Australia is a non-profit, non-government organisation and the national voice for the 3.6 million Australians living with chronic pain. - Chronic Pain Australia was founded in 2001. - The organisation runs National Pain Week, the National Pain Survey, PainLink support services and a national network of peer-led Pain Support Groups. - Medigrowth’s Adam Guskich said the sponsorship reflects the company’s commitment to improving outcomes for people living with chronic pain. - Guskich said cannabinoid therapeutics remain widely misunderstood. - Kellie Jade Ellis said partnerships like the one with Medigrowth are vital to National Pain Week’s success. - Ellis said sponsors help reach more Australians living with pain, amplify their voices and push for pain to be recognised as a National Health Priority Area. - Medigrowth’s announcement includes links to Medigrowth Australia, Chronic Pain Australia, Medigrowth on LinkedIn, Medigrowth on Instagram, Medigrowth on Facebook, Chronic Pain Australia on YouTube, Chronic Pain Australia on TikTok, Chronic Pain Australia on LinkedIn and Chronic Pain Australia on X.

Between the lines: - The partnership positions medicinal cannabis more squarely inside a public conversation about chronic pain treatment. - The survey data suggests interest in medicinal cannabis is now mainstream enough to be a major education and access issue, not just a niche topic. - Medigrowth is using the sponsorship to frame cannabinoid therapeutics as evidence-based care rather than a fringe option. - Chronic Pain Australia gains a corporate sponsor aligned with its push to increase awareness and policy attention.

What's next: - Medigrowth and Chronic Pain Australia will roll out National Pain Week programming from 26 to 31 July 2026. - The 2026 National Pain Report will be released with Medigrowth named as Gold Sponsor. - The partnership is aimed at driving more informed conversations about chronic pain care and medicinal cannabis during the campaign.

The bottom line: - Medigrowth is betting that education, visibility and survey-backed advocacy can accelerate acceptance of medicinal cannabis in chronic pain care.